BioticsAI: how to navigate the FDA, raise money, and motivate a team in healthtech

CEO BioticsAI Robbie Bustami spoke on the Build Mode podcast with an honest account of what it's really like to build an AI company in healthcare — from navigating FDA approval to conversations with investors and retaining talent.

Why healthcare is a special case

Most technology startups operate on the "ship and iterate" principle: release a feature, measure the reaction, refine. In healthcare, this logic breaks down. Every algorithm change that affects clinical decisions potentially requires FDA re-approval. Bustami described how BioticsAI built its processes with regulatory requirements in mind from the start. This isn't just bureaucracy — it's a different development philosophy: you think about validation and documentation first, then about release speed. Companies that try to "add compliance later" inevitably rewrite their architecture and lose months at a stage when the cost of error is particularly high.

FDA: how not to get stuck in bureaucracy

One of the key insights is reframing the regulator's role. Many startups view the FDA as an obstacle. Bustami proposes a different frame: the regulator sets a quality standard that protects both patients and the company's reputation. In practice, this means engaging with the FDA early, even before formal submission. Preliminary consultations help understand the regulator's expectations and avoid spending months preparing a package that will be returned with comments.

The typical approval path in healthtech AI includes:

• Determining product class (Class I, II, or III)
• Preparing a technical file with clinical data
• Preliminary FDA consultation (Pre-Sub meeting)
• Formal submission via the 510(k) or De Novo track
• Review period from several months to a year
• Post-market monitoring following approval

Fundraising with regulatory tail

Attracting investment in healthtech is a separate discipline. Venture investors accustomed to SaaS expect product-market fit within 18–24 months. In healthcare, this logic doesn't work: the regulatory path extends time horizons, and investment milestones look different. Bustami explained how the BioticsAI team learned to frame regulatory progress as an investment narrative. FDA Breakthrough Device Designation, first clinical partnerships, publications in peer-reviewed journals — all become maturity markers that specialized healthtech investors value.

Team motivation in a slow world

In technology startups, the usual fuel is frequent wins: a feature every two weeks, metric growth every month. In healthcare, development proceeds for months without visible results for users. This requires a different culture. At BioticsAI, they learned to celebrate intermediate milestones: first FDA conversations, first clinical partner, first successful test. This replaces the familiar dopamine signals and keeps the team focused on mission rather than short-term metrics.

What this means

Healthcare AI is not just the next market for LLMs. This is an industry where the cost of regulatory error is measured in lives and billion-dollar lawsuits. Startups that embed compliance in their culture from day one gain long-term competitive advantage — and increase the chances of navigating the full path from prototype to clinical application.